Key Points
DexCom expects $0.47 EPS and $1.17B revenue on April 30
Company has beaten EPS estimates in 3 of last 4 quarters
Strong 60% gross margins and $3.73 operating cash flow per share
Meyka rates DXCM B+ with 12 analyst buy ratings supporting stock
DexCom, Inc. (DXCM) will report second quarter 2026 earnings on April 30 after market close. Analysts expect the continuous glucose monitoring leader to deliver $0.47 earnings per share and $1.17 billion in revenue. The stock trades at $59.30, down 3.4% today, reflecting broader healthcare sector weakness. With a $22.88 billion market cap and strong analyst support (12 buy ratings versus 2 sells), investors are watching closely to see if DexCom maintains its growth momentum in the competitive diabetes care market.
Earnings Estimates and Analyst Expectations
Wall Street expects DexCom to post modest earnings this quarter. The consensus calls for $0.47 per share, down from the prior quarter’s $0.68 beat. Revenue guidance sits at $1.17 billion, representing steady growth from recent quarters. Twelve analysts rate the stock as a buy, while only two recommend selling, showing strong conviction in the company’s long-term prospects.
EPS Trend Analysis
DexCom has beaten earnings estimates in recent quarters. The company delivered $0.68 actual EPS versus $0.65 estimated in February 2026, and $0.61 actual versus $0.57 estimated in October 2025. This consistent outperformance suggests management executes well on guidance. However, the current $0.47 estimate represents a step down, likely reflecting seasonal patterns or conservative guidance.
Revenue Momentum
Revenue estimates of $1.17 billion align with DexCom’s recent trajectory. The company posted $1.26 billion in February and $1.21 billion in October 2025. Sequential growth has slowed, but year-over-year expansion remains solid. Analysts expect continued strength in international markets and new product adoption, particularly the DexCom G7 system.
Historical Performance and Beat/Miss Pattern
DexCom has demonstrated a strong track record of beating analyst expectations. Over the last four quarters, the company beat EPS estimates three times and revenue estimates twice, showing disciplined execution and conservative guidance practices.
Recent Quarter Results
In February 2026, DexCom beat EPS by $0.03 (actual $0.68 vs. estimate $0.65) and revenue by $76.7 million (actual $1.26B vs. estimate $1.18B). October 2025 showed similar strength with $0.04 EPS beat and $26.4 million revenue beat. July 2025 delivered $0.04 EPS beat but missed revenue slightly. This pattern suggests management guides conservatively on earnings but faces tougher revenue forecasting.
Prediction for April 30 Report
Based on historical trends, DexCom has a 75% probability of beating the $0.47 EPS estimate. The company’s consistent outperformance and strong operational execution support this outlook. Revenue could also exceed the $1.17 billion estimate, though by a smaller margin than EPS beats.
Key Metrics and Financial Health
DexCom maintains strong financial fundamentals supporting earnings growth. The company shows healthy profitability, solid cash generation, and manageable debt levels that provide flexibility for investment and shareholder returns.
Profitability and Margins
DexCom’s gross profit margin stands at 60.1%, reflecting the high-margin nature of medical device manufacturing. Operating margin of 19.6% demonstrates pricing power and operational efficiency. Net profit margin of 17.9% shows strong bottom-line conversion. These metrics rank well within the medical devices sector and support sustainable earnings growth.
Cash Flow Strength
Operating cash flow per share reached $3.73, while free cash flow per share totaled $2.79. The company generated $3.96 billion in operating cash flow over the trailing twelve months. This robust cash generation funds research and development, capital expenditures, and positions DexCom to weather market cycles.
Balance Sheet Quality
DexCom maintains a current ratio of 1.88, indicating strong short-term liquidity. Debt-to-equity stands at 0.51, a moderate level for a growth-stage medical device company. The company holds $5.17 per share in cash, providing strategic flexibility. Interest coverage of 64.7x shows minimal financial stress.
What Investors Should Watch
Several factors will determine market reaction to DexCom’s earnings report. Investors should focus on forward guidance, product adoption trends, and competitive positioning in the rapidly evolving CGM market.
Guidance and Outlook
Management’s guidance for Q3 and full-year 2026 will be critical. Investors want to see confidence in sustained growth despite recent stock weakness. Any commentary on pricing pressure, reimbursement changes, or competitive threats from Abbott and Medtronic will move the stock. Strong forward guidance could spark a relief rally.
Product Mix and International Growth
DexCom’s shift toward higher-margin products like G7 and international expansion are key growth drivers. Earnings commentary on G7 adoption rates, international revenue contribution, and market share gains will signal long-term competitive strength. Strong international growth would justify the current valuation.
Analyst Consensus and Meyka Grade
Meyka AI rates DXCM with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reflects solid fundamentals but acknowledges valuation concerns. With 12 buy ratings and only 2 sells, Wall Street remains constructive on DexCom’s prospects despite near-term stock pressure.
Final Thoughts
DexCom enters earnings with solid fundamentals including 60% gross margins and 12 analyst buy ratings, but faces valuation concerns reflected in its 16.7% one-year decline. The company typically beats its $0.47 EPS estimate and $1.17 billion revenue forecast. April 30’s earnings will be crucial to restore investor confidence through strong guidance and product momentum, particularly regarding G7 adoption and international growth.
FAQs
What EPS and revenue does Wall Street expect from DexCom’s April 30 earnings?
Analysts expect DexCom to report $0.47 earnings per share and $1.17 billion in revenue. These estimates represent steady performance but are below recent quarter results, likely reflecting seasonal patterns and conservative guidance practices.
Has DexCom beaten earnings estimates recently?
Yes. DexCom beat EPS estimates in three of the last four quarters, including $0.68 actual versus $0.65 estimated in February 2026. The company also beat revenue estimates twice recently, demonstrating disciplined guidance and strong execution.
What should investors watch during the earnings call?
Focus on forward guidance for Q3 and full-year 2026, G7 product adoption rates, international revenue growth, and management commentary on competitive pressures. Strong guidance and product momentum could spark a stock rally.
What is Meyka’s rating for DexCom stock?
Meyka AI rates DXCM with a B+ grade, reflecting solid fundamentals, strong financial metrics, and analyst consensus support. The rating factors in sector performance, growth trends, and valuation considerations. This grade is not investment advice.
Why has DexCom stock declined 16.7% over the past year?
The decline reflects valuation concerns, competitive pressures from Abbott and Medtronic, and broader healthcare sector weakness. Despite strong fundamentals with 60% gross margins and robust cash flow, investors worry about growth deceleration and market saturation.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)